

In the Claims

Please add the following claims.

- 
- 16. (New) In a method for expressing a transgenic product in a mammal comprising introducing into said mammal a transgene capable of expressing said transgenic product and administering to said mammal an immunosuppressant, the improvement comprising administering as the immunosuppressant p15-deoxyspergualin, anti-T-cell antibody, corticosteroid, azathioprine, or methotrexate in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 50% greater than the level of said product when said immunosuppressant is not administered.
17. (New) The method of Claim 16 wherein said immunosuppressant is administered in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 5 times greater than the level of said product when said immunosuppressant is not administered.
18. (New) The method of Claim 16 wherein said immunosuppressant is administered in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 10 times greater than the level of said product when said immunosuppressant is not administered.

19. (New) A method for identifying a substance which has immunosuppressant properties and which remains capable, after its administration to a mammal has been discontinued, of suppressing the immune response of said mammal to a transgenic cell which is contained in the mammal and which expresses a transgenic product, said method comprising the step of comparing the level of said transgenic product produced by a transgenic cell contained in a first mammal which has been administered said substance with the level of said transgenic product produced by a transgenic cell contained in a second mammal which has not been administered said substance, said levels being measured after the administration of said substance has been discontinued.
- DI  
cont
20. (New) A method according to Claim 19 wherein the level of said transgenic product in said first and second mammals is measured 15 or more days after the administration of said substance has been discontinued.
21. (New) A method according to Claim 19 wherein said transgenic cell is produced *in vivo* in said first and second mammals and the level of said transgenic product in said first and second mammals is monitored continuously from the time of the production of the transgenic cell.
22. (New) A method according to Claim 19 wherein the level of said transgenic product in said first and second mammals is monitored continuously from the first day following the discontinuation of the administration of said substance.--
-